Brain Tissue Binding Assay - Creative Bioarray

Services

Solutions

USA

Tel:
Fax:
Email:
Europe
Tel:
Email:

Brain tissue binding is an important concept in the field of neuroscience and pharmacology. It refers to the nonspecific binding of a compound to components within brain tissue, which can significantly reduce the amount of free, or unbound, drug available to interact with its target. It is important to note that free drug concentration (fu) is often one of the important determinants of a compound's potency and brain penetration. Understanding BTB enables researchers to forecast both blood-brain barrier distribution patterns and central nervous system penetration of compounds. Creative Bioarray's Brain Tissue Binding Service delivers dependable and high-quality data for pharmacokinetic/pharmacodynamic studies of compounds targeting the CNS.

The brain tissue binding of a drug influences its free fraction which in turn dictates the availability of a compound for its pharmacological action. Key implications include:

CNS Exposure: High BTB can lead to a low concentration of the free drug in the brain, potentially limiting the compound's effectiveness.
Target Engagement: The drug's optimal binding to the target site is essential for achieving the desired therapeutic effects.
Toxicity Risk: Excessive accumulation of the drug in the brain could potentially lead to off-target effects. By quantifying BTB, we help optimize drug candidates for improved brain penetration and safety profiles.

Our Brain Tissue Binding Assay

We employ a validated rapid equilibrium dialysis (RED) technique to measure unbound drug fraction (f_{u_brain}) in brain homogenates. The RED method places a drug compound in a sample chamber that is separated from a buffer chamber by a semipermeable membrane. When the system reaches equilibrium, only the free (unbound) drug is able to diffuse through the membrane into the buffer. The concentrations in both chambers are measured, which allows for an accurate determination of the unbound fraction (f_u,brain) and calculation of the unbound volume of distribution (V_u,d). Key features of our assay:

Species Specific: Such as rat, mouse and non-human primate tissue are available.
Sensitive: Accurate and precise quantification using LC-MS/MS.
Tailored: Drug concentrations and incubation conditions can be adjusted to the specific needs of the compound of interest.

Workflow:

Sample Submission: Clients provide their compounds, specifying the desired concentrations and species.
Tissue Preparation: Fresh or frozen brain tissue is homogenized to form a uniform tissue slurry.
Equilibrium Dialysis: The brain tissue homogenate is incubated with the compound of interest in the sample chamber of the RED device. The device is incubated until equilibrium is achieved (usually 4-6 hours) at 37°C.
Concentration Measurement: Samples are taken from both the tissue homogenate and the buffer chambers following dialysis.
Data Analysis: The drug concentration in both the tissue homogenate and buffer is quantified using a sensitive and selective analytical method (typically LC-MS/MS). The unbound fraction is calculated using the ratio of the two concentrations.
Reporting: A comprehensive report is delivered, including the calculated f_u,brain and a detailed breakdown of the experimental conditions and raw data.

Why Choose Us

Comprehensive Expertise: Decades of experience in CNS pharmacokinetics and tissue binding studies.
Flexible Study Design: Tailored protocols to fit small molecule, biologic, or novel modality projects.
High Sensitivity & Precision: State-of-the-art LC-MS/MS platforms ensure robust and accurate results.
Regulatory Support: Data packages designed to meet requirements for regulatory submissions.
Client-Centered Approach: Collaborative project management with transparent communication.

FAQ

Why is brain tissue binding important for CNS drug development?

Because only the unbound drug can cross membranes and interact with receptors, brain tissue binding helps determine the effective concentration available for pharmacological action.

How do brain tissue binding results translate to in vivo studies?

In vitro data provide a foundation for predicting CNS exposure and guiding dose selection. When integrated with in vivo pharmacokinetic data, they support translational modeling for clinical relevance.

How does brain tissue binding differ from plasma protein binding?

Both are forms of nonspecific binding, but they occur in different matrices. Plasma protein binding involves interactions with circulating proteins like albumin and alpha-1-acid glycoprotein. Brain tissue binding involves interactions with lipids, proteins, and other cellular components within the brain tissue itself. Both parameters are crucial for understanding drug distribution.

Our customer service representatives are available 24 hours a day, 7 days a week. Inquiry

For research use only. Not for any other purpose.